MedTrace Logo

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

NCT05291845 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2025-06-12

No results posted yet for this study

Summary

To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy

Conditions

Interventions

BIOLOGICAL

Candida antigen vaccine

we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group

BIOLOGICAL

Bivalent HPV vaccine

we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Reham Essam, MD · Zagazig University

  • Ahmad Nofal, MD · Zagazig University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-03
Primary Completion
2025-10-03
Completion
2025-12-06

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05291845 on ClinicalTrials.gov